Baba M, Hideshima T, Yamashita Y, Shirakusa T
Second Department of Surgery, School of Medicine, Fukuoka University, Fukuoka 814-0180, Japan.
Oncol Rep. 1998 Sep-Oct;5(5):1141-6. doi: 10.3892/or.5.5.1141.
Bispecific antibody, OH1 was developed, which simultaneously recognizes CD3 on T cells and carcinoembryonic antigen (CEA) on tumor cells. Although there was not significant difference, PBMCs pretreated with OH1 showed tendency to prolong survival of KATO III-injected SCID mice compared with control groups. although cytotoxicity of LAK cells from cancer-bearing patients was suppressed compared with that of cells of healthy donors, LAK cells from the patients pretreated with OH1 showed significantly increased cytotoxicity against KATO III cells. These results suggest that OH1 could be useful in immunotherapy with LAK cells for carcinomas that express CEA on the membrane.
双特异性抗体OH1被研发出来，它能同时识别T细胞上的CD3和肿瘤细胞上的癌胚抗原（CEA）。尽管没有显著差异，但与对照组相比，用OH1预处理的外周血单核细胞（PBMCs）显示出延长接种KATO III的SCID小鼠生存期的趋势。尽管荷癌患者的淋巴因子激活的杀伤细胞（LAK细胞）的细胞毒性与健康供体的细胞相比受到抑制，但用OH1预处理的患者的LAK细胞对KATO III细胞的细胞毒性显著增加。这些结果表明，OH1可用于对膜上表达CEA的癌症进行LAK细胞免疫治疗。
